Clues To Long-Term HIV Survival

14 August 1994

Presentations at the 10th International Conference on AIDS, held in Yokohama, Japan, have suggested that people who seem to survive for a long period of time infected with HIV yet still remain asymptomatic may hold a clue towards understanding how best to target therapy for the disease.

David Ho, a researcher at the Aaron Diamond AIDS Research Center in the USA, said that data from nine men and one woman who have remained asymptomatic for more than 12 years have shown a retention of high levels of CD8 cells. Dr Ho added that when CD8 cells were removed from the blood of these patients in vitro HIV began to grow rapi-dly. Adding new CD8 cells once again controlled the virus. However, he adds that it is still not understood how such individuals remain asymptomatic, and it is not expected to be simple. Providing that the conditions in these individuals can be recreated it should be possible to keep patients symptom-free, he noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight